Chardan Capital analyst Keay Nakae maintained Dyne Therapeutics with a Buy and lowered the price target from $50 to $38.

Dyne also reported new positive long-term data from adult DM1 patients enrolled in the randomized, placebo-controlled multiple ascending dose (MAD) portion of the DYNE-101 ACHIEVE trial, including ...

Dyne Therapeutics Inc. (NASDAQ: DYN) is one of the best biotech stocks to invest in now. On June 17, Dyne Therapeutics announced that the FDA granted Breakthrough Therapy Designation to DYNE-101 ...